Norovirus infectious disease

Researchers are testing an experimental vaccine called INT101 to see if it is safe and can trigger an immune response against norovirus. The trial enrolls about 30 healthy adults aged 19 to 48. Participants receive either a low dose, a high dose, or a placebo as three intramuscul…

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This study tests an experimental oral drug called CDI-988 in 40 healthy adults aged 18 to 49. Participants receive either the drug or a placebo before being exposed to norovirus, the highly contagious stomach bug. The goal is to see if CDI-988 reduces vomiting and diarrhea compar…

This early-stage trial tests whether specially grown immune cells (norovirus-specific T-cells) can safely treat chronic norovirus infections in people with weakened immune systems, such as those who had a stem cell or organ transplant. The study will enroll 48 participants and gi…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…